Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020200305 - USE OF PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYUREA

Publication Number WO/2020/200305
Publication Date 08.10.2020
International Application No. PCT/CN2020/083159
International Filing Date 03.04.2020
IPC
A61K 31/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
17having the group N-C(O)-N or N-C(S)-N, e.g. urea, thiourea, carmustine
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4365 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
4365the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/616 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
612having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
616by carboxylic acids, e.g. acetylsalicylic acid
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants
  • 吉林大学 JILIN UNIVERSITY [CN]/[CN]
  • 中国医学科学院药物研究所 INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL [CN]/[CN]
Inventors
  • 佟倩 TONG, Qian
  • 王琰 WANG, Yan
  • 蒋建东 JIANG, Jiandong
  • 张显峰 ZHANG, Xianfeng
  • 马殊荣 MA, Shurong
  • 于金波 YU, Jinbo
  • 丛林 CONG, Lin
Agents
  • 北京集佳知识产权代理有限公司 UNITALEN ATTORNEYS AT LAW
Priority Data
201910270431.204.04.2019CN
Publication Language Chinese (ZH)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF PHARMACEUTICAL COMPOSITION CONTAINING HYDROXYUREA
(FR) UTILISATION D'UNE COMPOSITION PHARMACEUTIQUE CONTENANT DE L'HYDROXYURÉE
(ZH) 一种含羟基脲的药物组合物的应用
Abstract
(EN)
Provided is the use of a pharmaceutical composition containing hydroxyurea, wherein the hydroxyurea or a pharmaceutically acceptable salt thereof is used in the preparation of a drug for preventing and/or treating atherosclerosis. Experimental results show: after oral administration of a combination of hydroxyurea, aspirin and clopidogrel bisulfate, fat and porridge-like lesion regions on aortic intima are significantly reduced, the effect on atherosclerosis is obvious (plaque inhibition degree of 85%), the concentrations of blood glucose, triglyceride, total cholesterol, and low-density lipoprotein cholesterol are decreased, and glucose and lipid metabolism disorder is significantly improved; after oral administration of a combination of hydroxyurea, aspirin, clopidogrel bisulfate and atorvastatin calcium, fat and porridge-like lesion regions on aortic intima are further significantly reduced, and atherosclerosis is essentially cured (plaque inhibition degree of 91%). The combinations of drugs at this dose have an outstanding therapeutic effect in the prevention and/or treatment of atherosclerosis.
(FR)
L'invention concerne l'utilisation d'une composition pharmaceutique contenant de l'hydroxyurée, l'hydroxyurée ou un sel pharmaceutiquement acceptable de celle-ci étant utilisée dans la préparation d'un médicament pour la prévention et/ou le traitement de l'athérosclérose. Les résultats expérimentaux montrent que : après l'administration orale d'une combinaison d'hydroxyurée, d'aspirine et de bisulfate de clopidogrel, de la graisse et des régions de lésion de type gruau présentes sur l'intima aortique sont significativement réduites, l'effet sur l'athérosclérose est manifeste (degré d'inhibition de plaque de 85 %), des concentrations de glucose sanguin, de triglycéride, de cholestérol total et de cholestérol à lipoprotéines de faible densité sont réduites, et un trouble du métabolisme du glucose et des lipides est significativement amélioré ; après l'administration orale d'une combinaison d'hydroxyurée, d'aspirine, de bisulfate de clopidogrel et d'atorvastatine calcique, la graisse et les régions de lésion de type gruau présentes sur l'intima aortique sont encore plus significativement réduites, et l'athérosclérose est essentiellement guérie (degré d'inhibition de plaque de 91 %). Les associations médicamenteuses dans de telles proportions ont un effet thérapeutique remarquable dans la prévention et/ou le traitement de l'athérosclérose.
(ZH)
提供了一种含羟基脲的药物组合物的应用,将含羟基脲或其药学上可接受的盐用于制备预防和/或治疗动脉粥样硬化症的药物。实验结果表明:口服羟基脲及阿司匹林、硫酸氢氯吡格雷的组合后,主动脉内膜脂肪及粥糜样病灶区域明显缩小,对动脉粥样硬化症的药效十分明显(斑块抑制程度85%),血中葡萄糖,甘油三酯,总胆固醇,低密度脂蛋白胆固醇浓度降低,糖脂代谢紊乱显著改善;口服羟基脲、阿司匹林、硫酸氢氯吡格雷及阿托伐他汀钙的组合后,主动脉内膜脂肪及粥糜样病灶区域进一步明显缩小并基本治愈动脉粥样硬化症(斑块抑制程度91%)。该剂量下的药物组合在预防和/或治疗动脉粥样硬化症中具有突出的治疗效果。
Latest bibliographic data on file with the International Bureau